Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Fast Is The Apixaban Market Expected to Grow Between 2025 And 2029?

The size of the apixaban market has witnessed substantial growth in the recent past. The market is set to expand from $2.92 billion in 2024 to $3.19 billion in 2025, experiencing a compound annual growth rate (CAGR) of 9.2%. Factors contributing to this growth during the historic period include greater occurrences of atrial fibrillation, an aging demographic, regulatory permissions and scaling, positive clinical results, and a transition from warfarin to NOACs.

What Growth Rate Is Anticipated for the Apixaban Market in the Coming Years?

The market size of apixaban is anticipated to witness significant expansion in the coming years, reaching $4.48 billion by 2029, with a Compound Annual Growth Rate (CAGR) of 8.8%. The projected growth during the forecast period is due to the ongoing prevalence of cardiovascular diseases, enhanced awareness and diagnostic procedures, growth in developing markets, an aging global populace, and revisions in health policy and reimbursement. Notable trends for the forecast period consist of improvements in drug delivery mechanisms, increased research and development activities, innovation, collaborations, FDA approval for apixaban, and the integration of digital health and telemedicine.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15979&type=smp

Who Are the Leading Companies in the Apixaban Market?

Major companies operating in the apixaban market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Sanofi S.A., Bristol-Myers Squibb Company, Eli Lilly and Company, Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Sandoz Group AG, Daiichi Sankyo Company Limited, Fresenius Kabi AG, Hetero Drugs Ltd, Eisai Co. Ltd, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Dr. Reddy’s Laboratories Ltd., Cipla Limited, Aspen Pharmacare Holdings Limited, Lupin Limited, Glenmark Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd, Medichem S.A., Centaur Pharmaceuticals Pvt. Ltd., Simson Pharma Limited, OPOCRIN SPA, Pinnacle Life Sciences Private Limited

What Are the Key Drivers of the Apixaban Market?

The escalating incidences of cardiovascular diseases are anticipated to drive the expansion of the apixaban market. The term “cardiovascular disease” refers to an array of conditions impacting the heart and blood vessels, such as coronary artery disease, stroke, and heart failure. These diseases are increasingly prevalent due to inactive lifestyles, subpar eating habits, smoking, obesity, hypertension, diabetes, and the aging populace. Apixaban plays a significant role in cardiovascular disease management, as it helps lower the risk of blood clots, thereby preventing conditions like stroke, deep vein thrombosis, and pulmonary embolism. For example, in January 2024, the American Heart Association, a non-profit organization based in the United States, reported that there were 931,578 deaths from cardiovascular diseases, marking a slight increase of less than 3,000 fatalities from the 928,741 registered in 2023. Consequently, the escalating incidences of cardiovascular diseases are contributing to the growth of the apixaban market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=15979&type=smp

What Are the Key Market Segments in the Apixaban Industry?

The apixaban market covered in this report is segmented –

1) By Dosage Form: Capsule, Tablets

2) By Application: Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE)

3) By End-Users: Hospitals, Homecare, Specialty Clinics, Other End-Users

Subsegments:

1) By Capsule: 2.5 mg Capsule, 5 mg Capsule

2) By Tablets: 2.5 mg Tablet, 5 mg Tablet

What Are the Latest Trends in the Apixaban Market?

Leading enterprises in the apixaban market are concentrating on introducing novel products, such as generic anticoagulant medications, to enhance patient affordability and accessibility. These firms aim to expand their market penetration and competitive edge. A generic anticoagulant drug is one that prevents blood clots by blocking various elements of the coagulation pathway, thereby mitigating the risk of stroke and other heart-related events. For example, Tiefenbacher Pharmaceuticals, a German healthcare firm, debuted a generic variant of Apixaban in Canada in October 2022. This orally ingested anticoagulant is used for post-elective knee or hip replacement prophylaxis, prevention of stroke in atrial fibrillation, and treatment of deep vein thrombosis and pulmonary embolism, serving a wide range of thrombotic conditions. The firm formulated 2.5 mg and 5 mg anticoagulant tablets in their Indian labs for distribution in Canada via partnerships with generic pharmaceutical firms, preceding a subsequent release in other international markets. This well-thought-out move fosters substantial savings for global healthcare structures and augments access to treatments that can significantly improve patients’ lives.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/apixaban-global-market-report

What Are the Key Regional Markets in the Apixaban Industry?

North America was the largest region in the apixaban market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the apixaban market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15979

This Report Delivers Insight On:

1. How big is the apixaban market, and how is it changing globally?

2. Who are the major companies in the apixaban market, and how are they performing?

3. What are the key opportunities and risks in the apixaban market right now?

4. Which products or customer segments are growing the most in the apixaban market?

5. What factors are helping or slowing down the growth of the apixaban market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model